2 June 2022 - PDS Biotech has been granted fast track designation for PDS0101 in combination with Keytruda (pembrolizumab) for the treatment of recurrent or metastatic HPV16 positive head and neck cancer
PDS Biotechnology Corporation today announced that the U.S. FDA has granted fast track designation to PDS0101 in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab).